Advertisement
U.S. markets open in 5 hours 2 minutes
Advertisement

Zymeworks Inc. (ZYME)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
8.87+0.05 (+0.57%)
At close: 04:00PM EST
8.68 -0.19 (-2.14%)
After hours: 05:30PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Shooting Star

Shooting Star

Performance Outlook
Previous Close8.82
Open8.95
Bid8.67 x 1000
Ask9.42 x 800
Day's Range8.86 - 9.34
52 Week Range5.76 - 10.80
Volume499,517
Avg. Volume371,491
Market Cap620.918M
Beta (5Y Monthly)0.88
PE Ratio (TTM)2.75
EPS (TTM)3.23
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.02
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ZYME

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zymeworks Inc.
    Daily – Vickers Top Buyers & Sellers for 11/30/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    22 hours agoArgus Research
View more
  • GlobeNewswire

    Zymeworks Announces Participation in Upcoming Investor Conference

    VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on January 8-11, 2024 and a corporate presentation on January 11th, 2024 at 8:15 am Pacific Time. The presentation and web

  • GlobeNewswire

    Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results

    Net loss for the first nine months of 2023 decreased by 44% as compared to the same period in 2022Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyondUpdated clinical results from Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) presented by our partner BeiGene at the European Socie

  • GlobeNewswire

    Zymeworks Announces Participation in Upcoming Investor Conferences

    VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on November 14th at 11:30 am Greenwich Mean Time in London, UK.Stifel 2023 Healthcare Conference: